We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Agreed and hopefully I'll be able to top up here if things work out elsewhere :-)
Good to speak with you Saint but we can all be happy with our decision to be in here with so much potential news coming down the pipe.
Indeed Ivy. I believe AVACT raised at £1.20 so for me anything under that is a good opportunity. This along with all the collaborations / milestone payments has enforced my belief. I'm also in HEMO. Very undervalued IMO and the SP woe's were caused by a foolish agreement with Mint capital and CLN's. Those have now been confined to history and the company has a few shots at goal. Some very good appointments lately and In collaboration with Penn Uni. Hopefully into clinical trials with their Car-T therapy by year end. CEO has stated that they have enough cash to see them through 2023. RM a very good endorsement for everyone here.
Yep Saint opinions will always be split on these posters with big followings but at least Myles always posted really comprehensive research to back up his views.
One thing all 3 quoted Company s have in common is they have all had game changing capital raises and when you have that in bio pharma like here it really gives you confidence to buy around that level as puts a floor under price,removes any need for further raises for a very long time and of course if you get the endorsement of great funds like RM that us great for confidence.
Thanks BOJO. All funds tied up at the moment but will definitely take a look should the situation change. Cheers.
Worth looking at Angle Plc also Saint, but you may know that from Avacta as some are always swapping between the two. Also has a TG group for Parsortix which is second to none for research.
I chose Scancell for my slow and steady... Oh boy is it slow! Still my favourite mind.
Hi Ivy. Yes that's probably it. Yes some people treat Myles like the Messiah and with his large following he definitely has influence. A lot of the stuff he posts is very good but you can take an educated guess as to when he's trading a little. I tend to listen then research as much as I can. I averaged down massively there when it dropped to around 45p a while back so am happy with my holding. I have great hope for both companies and am happy to ride the waves.
Cheers Saint,
May be it just appears that way as both 3 Month charts exhibit similarities but fluctuating in a range of 97-130 rather than 12-15p may give impression of being more reactive to news.My main point is that one respected guy like Myles can really help publicise a share when it went from 15-200p albeit being helped by the Covid bubble.
Have not been in for a couple of years but again presume there is a large TG group which may be pretty active.
No worries Ruck. Agreed - I'm trying to get away from the one trick pony trap too. Happy to learn from more knowledgeable holders here.
Saint,
Thanks. Shows the danger of knowing a lot about a few shares (or just one) and nothing about others.
* looking forward. Fat fingers syndrome.
Hi all. Don't post here much but have been an avid reader for quite some time. I have interests in both companies and I have to disagree that Avactas share price reacts more on news. They have been running clinical trials at several centres for nearly 12 months and we've only had good news. In this time we've had 2 dose escalations and are currently using a dose higher than the standard Doxorubicin with no maximum tolerated dose found. We're due an update in Q3 22 and if everything is progressing as expected a re-rate could be on the card (hopefully). The share price however has dropped and I really can't understand why - aside from the LFT debacle.
I'm hoping both companies come good - firstly for the benefit of patients and also for shareholders.
Good luck to all and looking for the next update here.
Agree Burble but would add one additional point.
Whilst we all want avoid being “ ramped” by some well known individuals and I want to be clear I am not talking about anyone on LSE or ADVFN but certain people who frequent other SM channels who pick upon usually not very good shares( which again is completely the opposite to here) and have lots of followers so you get the spike and immediate fall back.
However there are also a number of respected commentators who also have a large number of followers who can influence the SP in a much more positive way and often they may be involved in retail favourites like AVCT and likes of Myles McNulty if still in it.
I am only aware of one of these type of guys involved in SCLP but again don’t frequent the BBs and tend to only promote if news which they have done in past.
Only my thoughts but most of influence on any AIM stocks does not correlate with BB posts.
Ivy, burble,
Thanks, those were pretty much my thoughts as well. I think there are companies that are just unfashionable. I think there is a need for a non technical, commercial arm to sell the concept and make them "fashionable".
I did not get the significance of the RNS from the title. I thought it was a re-hashed "first patient dosed" announcing the second patient dosed - not a lot of progress. You have to dig into the detail to realise it is first patient dosed in the SECOND cohort, the implications of which were quite significant as per the discussion that ensued yesterday.
Hi Ruck,
As others have said the SP reaction is purely down to this is not a retail favourite like AVCT and as such does not get the same level of exposure and noise.
It is one of the vagaries of AIM that no matter how good the fundamentals then “ sentiment” which often manifests itself outside of BBs is often much more important in moving the SP.
If the science/ data is clearly monetised then that wider sentiment is easily attracted and if you recall the really big rises here were on the initial mention of a Covid Vax at a time when anything Covid tekated was getting huge attention and the w/ end with great coverage in Press/Sky etc which does cast a much wider influence.
Ruck
I've been thinking about this and I think Ivy's comments earlier regarding RNS titles has someway to go for it. I know in the past this board has spoken about the overall naming of SCLP being 'Scancell Holdings' rather than 'Scancell Pharma' or words to that effect.
What I would say is across many different companies, how an RNS title is worded can really generate energy within a share price but also can do the opposite. You see companies where RNSs scream 'this is the best thing ever' but when you start digging a little deeper and doing more research into a company, you realise they're saying one thing and behind the scenes things aren't as rosy as they could be.
LD and the team have generally been pretty factual about things and quite demure about findings. They're not shouting from the rooftops at every single announcement, but also what they're saying is v.factual and difficult to find fault in. Some investors like this, but others struggle with the lack of announcements or blowing their own trumpet at each and every development.
For me, I would rather the SP reacted on facts, figures and data, rather than pure sentiment. That way when it goes up, it goes up slow and steady, rather than having this pendulum effect you see on other shares.
IPad,
I wouldn't say Avacta is a direct competitor per se. Yes they are a biotech with some focus on oncology but I wouldn't see them as a competitor. Their affimer technology is a non-antibody scaffold based technology which has it's own pros and cons. The real overlap between the two companies comes with our antibody platforms, but I would generally say from a 'using a protein which binds to a target to treat cancer' aspect. That's pretty much where the similarities finish.
I think the original comment was more aimed at the fact Avacta's share price reacts to announcements, whereas Scancells doesn't.
WTP,
"and how anemic Scancells reaction normally is"
Any ideas why that might be?
I think the comparison came about because of market reaction to news, and how anemic Scancells reaction normally is in comparison, rather than competitors.
Personally I pad am not worried about it being a competitor but is a retail favourite so does attract a lot of interest.
The beauty here is the number of platforms and multiple shots at goal.The potential of all the platforms whether Affimers (AVCT), Aptamers and many other approaches by many Companys remains just that potential until they are monetised or Approved and that is the same throughout they will fail or succeed by data.
Not sure why this thread started but I’ve had a look at said company. Is it a serious competitor to Scancell ?
Ok let’s look forward to next Rns . What do we think will be next ?
Morning WTP,
I am sure the messaging on the RNSs is not to keep this under the radar but simply a historical SCLP tendency like many bio pharma who have scientists scripting them to be conservative, factual and maybe understated.
What I find most useful in these RNSs is to read the comments of LD who in fairness usually accompany’s them with a comment and watch what language she uses.
Although there is much more work to be done in this trial and news to come including the more important potentially transformational bits,the RNS imo was significant in that it confirmed there were no safety issues with the first use of Modi 1 in humans even if very low numbers.
Given the trials and tribulations of KD getting this into the clinic I think her words reflected the relief as much as anything.
It may have been “ expected” by sone based on pre clinical work but I would not underestimate that this was not guaranteed to transfer into humans and of course any bad news re the safety would have been a major negative so let us just be pleased they have delivered whether the wider market see this or not.
Or does it give the pharma research fellows a heads up to buy shares , before the traders catch on ?
Fair point C7.